Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00783393
First received: October 30, 2008
Last updated: May 1, 2014
Last verified: May 2014
  Purpose

The primary purpose of the study is to evaluate the efficacy (overall response) and safety of temozolomide in Step 1 at the dose and regimen approved in the US and the EU countries (28 day cycles of temozolomide at 150 to 200 mg/m2 once daily for 5 consecutive days with a 23 day rest period) in patients with anaplastic astrocytoma at first relapse.


Condition Intervention Phase
Astrocytoma
Drug: Temozolomide
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Overall response in Step 1 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Incidence rate and severity of adverse events with administration of temozolomide in Step 1 [ Time Frame: 7 months (during temozolomide administration for 6 months and follow-up for 1 month) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Progression-free survival in Step 1 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Overall survival in Step 1 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Tumor response in Step 1 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Neurological improvement in Step 1 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Progression-free survival, overall survival, overall response, effect on neurological symptoms, and safety in Step 2 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Progression-free survival in Step 2 [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
  • Overall survival in Step 2 [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
  • Overall response in Step 2 [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
  • Effect on neurological symptoms in Step 2 [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
  • Safety in Step 2 [ Time Frame: Up to 2 years ] [ Designated as safety issue: Yes ]

Enrollment: 32
Study Start Date: September 2003
Study Completion Date: October 2006
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single arm

The study consists of two steps:

  • Step 1, the therapeutic study phase, comprising six cycles of treatment with temozolomide, and
  • Step 2, the long-term treatment phase, where subjects with at least disease stabilization at the end of Step 1 may continue temozolomide treatment until unacceptable toxicity or disease progression occur, up to a maximum of 2 years from the start of treatment in Cycle 1.
Drug: Temozolomide
Temozolomide orally once daily for 5 consecutive days followed by a 23 day rest period to complete a 28 day treatment cycle. In Cycle 1, temozolomide will be administered at 150 mg/m2/day; in Cycle 2 and subsequent cycles, it will be administered at 100, 150, or 200 mg/m2, depending on hematology test results and adverse events observed.
Other Name: Temodal, Temodar, SCH 052365

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must have histologically confirmed anaplastic astrocytoma on the tentorium at first relapse, and satisfy the following:

    • unequivocal evidence of tumor recurrence or aggravation by MRI scan after treatment for initial onset; the lesions must be measurable;
    • anaplastic astrocytoma diagnosed histologically by the last pathological diagnostic tests (including initial diagnosis) prior to initial administration of temozolomide;
    • tissue samples available for Central Pathologic Reviewer;
    • pathologic diagnosis report by the study-conducting medical institution must be available for the sponsor.
  • MRI-related criteria:

    • MRI scan performed within 14 days before initial temozolomide administration;
    • assessable tumor site confirmed by MRI;
    • dosage of steroidal agents not increased within 7 days before MRI prior to initial temozolomide administration, except for postoperative subjects for first relapse;
    • MRI performed at the Principal Investigator's study location or designated radiology facility during the study.
  • Age >=18 years, either sex, inpatients or outpatients.
  • Use of medically approved contraception methods in fertile subjects.
  • Karnofsky performance status >=70.
  • Adequate clinically laboratory values obtained within 14 days before initial temozolomide administration.
  • Criteria regarding treatment of initial onset:

    • tumor biopsy, regardless of tumor resection at initial diagnosis;
    • prior radiation therapy;
    • prior chemotherapy with up to one nitrosourea-containing regimen.
  • Tumor may or may not have been surgically resected at first relapse, but residual measurable disease is required.
  • For subjects who had surgical resection of tumor at first relapse:

    • MRI scan must have been performed within 72 hours after surgery.
    • the dose of steroidal agents must be reduced before temozolomide administration.
  • Life expectancy >=12 weeks.
  • Written informed consent obtained.

Exclusion Criteria:

  • History of treatment with dacarbazine.
  • Subjects who received chemotherapy within 6 weeks before initial temozolomide administration.
  • Subjects who received interstitial radiotherapy or stereotactic radiosurgery.
  • Subjects who completed radiotherapy within 12 weeks before initial temozolomide administration.
  • Surgery at first relapse (including biopsy) within 1 week before initial temozolomide administration.
  • Subjects not recovered from acute toxicity due to previous therapy.
  • High-risk subjects with complication of diseases other than malignant tumor, or who require systemic administration of antibiotics for infection.
  • Previous or concurrent malignancies at other sites.
  • Pregnant or nursing women.
  • Women of childbearing potential not using an effective method of contraception.
  • Subjects previously treated with temozolomide.
  • Participation in an ongoing clinical study, or in other clinical studies within 6 months before initial temozolomide administration.
  • Subjects found inappropriate for the study by the investigator or subinvestigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00783393     History of Changes
Other Study ID Numbers: P03745, JPC02-351-21
Study First Received: October 30, 2008
Last Updated: May 1, 2014
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

Additional relevant MeSH terms:
Astrocytoma
Glioma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Temozolomide
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014